Cytochrome P-450 CYP3A Inhibitors
"Cytochrome P-450 CYP3A Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP3A.
| Descriptor ID |
D065692
|
| MeSH Number(s) |
D27.505.389.500.503 D27.505.519.389.335.503
|
| Concept/Terms |
Cytochrome P-450 CYP3A Inhibitors- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P 450 CYP3A Inhibitors
- CYP3A Inhibitors
- Inhibitors, CYP3A
- P450 CYP3A Inhibitors
- Inhibitors, P450 CYP3A
Cytochrome P-450 CYP3A7 Inhibitors- Cytochrome P-450 CYP3A7 Inhibitors
- Cytochrome P 450 CYP3A7 Inhibitors
- P450 CYP3A7 Inhibitors
- CYP3A7 Inhibitors, P450
- Inhibitors, P450 CYP3A7
- CYP3A7 Inhibitors
- Inhibitors, CYP3A7
Cytochrome P-450 CYP3A5 Inhibitors- Cytochrome P-450 CYP3A5 Inhibitors
- Cytochrome P 450 CYP3A5 Inhibitors
- P450 CYP3A5 Inhibitors
- CYP3A5 Inhibitors, P450
- CYP3A5 Inhibitors
- Inhibitors, CYP3A5
Cytochrome P-450 CYP3A4 Inhibitors- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P 450 CYP3A4 Inhibitors
- P450 CYP3A4 Inhibitors
- Inhibitors, P450 CYP3A4
- CYP3A4 Inhibitors
- Inhibitors, CYP3A4
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP3A Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP3A Inhibitors".
This graph shows the total number of publications written about "Cytochrome P-450 CYP3A Inhibitors" by people in this website by year, and whether "Cytochrome P-450 CYP3A Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 3 | 3 |
| 2011 | 0 | 1 | 1 |
| 2014 | 0 | 2 | 2 |
| 2015 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cytochrome P-450 CYP3A Inhibitors" by people in Profiles.
-
Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087). Clin Cancer Res. 2023 12 15; 29(24):5038-5046.
-
Identifying the Reactive Metabolites of Tyrosine Kinase Inhibitor Pexidartinib In Vitro Using LC-MS-Based Metabolomic Approaches. Chem Res Toxicol. 2023 08 21; 36(8):1427-1438.
-
Fentanyl Toxicity Related to Concomitant Use of Ciprofloxacin and its Effects as a CYP3A4 Inhibitor. J Pain Symptom Manage. 2023 08; 66(2):e307-e309.
-
Safety and Tolerability of Carboplatin and Paclitaxel in Cancer Patients with HIV (AMC-078), an AIDS Malignancy Consortium (AMC) Study. Oncologist. 2022 08 05; 27(8):623-e624.
-
Group based trajectory modeling to assess adherence to oral anticoagulants among atrial fibrillation patients with comorbidities: a retrospective study. Int J Clin Pharm. 2022 Aug; 44(4):966-974.
-
Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3-11 Years with Hepatitis C Genotype 1a. Adv Ther. 2020 07; 37(7):3299-3310.
-
Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies. Br J Clin Pharmacol. 2019 03; 85(3):530-539.
-
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018 03; 93(3):401-407.
-
An evaluation of the CYP2D6 and CYP3A4 inhibition potential of metoprolol metabolites and their contribution to drug-drug and drug-herb interaction by LC-ESI/MS/MS. Biomed Chromatogr. 2016 Oct; 30(10):1556-72.
-
Metabolomics reveals the formation of aldehydes and iminium in gefitinib metabolism. Biochem Pharmacol. 2015 Sep 01; 97(1):111-21.